Biotech Values

[rph_in_wi]

"Further study of a 10 mg dose of squalamine is certainly warranted scientifically based on our preliminary results from the MSI-1256F-207 study."

What does that mean? Was it based on adverse events at the higher doses or did the PK info cause Genaera to feel that the drug's distribution/elimination characteristics enabled a lower dose. The statements' ambiguity causes me to lean towards negative assumptions.

Any correction to my thoughts are appreciated.
RPh